#symtuza

[pozmagazine]

Rapidly Starting Symtuza After HIV Diagnosis Tied to High Viral Suppression

Researchers enrolled participants within 14 days of their HIV diagnosis.

People who rapidly start Symtuza (darunavir/cobicistat/tenofovir alafenamide/emtricitabine) following an HIV diagnosis have a high rate of viral suppression a year later.

Janssen’s Symtuza was approved in July 2018 for those starting antiretroviral treatment for the first time as well as certain people switching from a different regimen who have a fully suppressed viral load.

[pozmagazine]

FDA Approves Janssen’s Symtuza for HIV Treatment

The Food and Drug Administration (FDA) has approved Janssen’s single-tablet regimen for the treatment of HIV in adults, Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide). The tablet is approved for people who are starting antiretroviral (ARV) treatment for the first time as well as certain people who are switching from another HIV regimen and have a fully suppressed virus.

[fundacionluchandovenceras]

SYMTUZA DRV/COBI/FTC/TAF Darunavir / cobicistat / emtricitabina / fumarato de Alafenamida de Tenofovir. Combinación Farmaceutica. . . . . . #symtuza #darunavir #cobicistat #emtricitabina #alafenamidadetenofovir #alafenamida #tenofovir #arv #retrovirrales #antiretrovirrales #salud #saludresponsable #saludybienestar #concienciasocial https://www.instagram.com/p/CBMvI8tjx_b/?igshid=147q8tv2vmncj